Literature DB >> 11219875

Using bisphosphonates to control the pain of bone metastases: evidence-based guidelines for palliative care.

K Mannix1, S H Ahmedzai, H Anderson, M Bennett, M Lloyd-Williams, A Wilcock.   

Abstract

This work was undertaken by the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland (APM) as a demonstration project in developing clinical guidelines relevant to palliative care from a pragmatic approach to literature review and grading of clinical evidence. CANCERLIT and Embase were searched for relevant papers written in English, published since 1980. Each study identified was rated against agreed criteria for levels of evidence. Most studies were not specifically designed to define speed of response, and were not undertaken in palliative care patients. Thus, careful reading and grading of each study was necessary. Sufficient evidence was identified to make recommendations for clinical practice in a palliative care population of patients, and areas for future research have been identified. Bisphosphonates appear to have a role in managing pain from metastases which has been refractory to conventional analgesic management and where oncological or orthopaedic intervention is delayed or inappropriate.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11219875     DOI: 10.1191/026921600701536372

Source DB:  PubMed          Journal:  Palliat Med        ISSN: 0269-2163            Impact factor:   4.762


  3 in total

1.  Effects of two administration schemes of intramuscular clodronic acid on bone mineral density: a randomized, open-label, parallel-group study.

Authors:  Bruno Frediani
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

Review 2.  Quality Assessment of Cancer Pain Clinical Practice Guidelines.

Authors:  Zhigang Zhang; Xiao Cao; Qi Wang; Qiuyu Yang; Mingyao Sun; Long Ge; Jinhui Tian
Journal:  Front Oncol       Date:  2022-05-27       Impact factor: 5.738

3.  Improved efficacy of intramuscular weekly administration of clodronate 200 mg (100 mg twice weekly) compared with 100 mg (once weekly) for increasing bone mineral density in postmenopausal osteoporosis.

Authors:  Bruno Frediani; Ilaria Bertoldi; Serena Pierguidi; Antonella Nicosia; Valentina Picerno; Georgios Filippou; Luca Cantarini; Mauro Galeazzi
Journal:  Clin Drug Investig       Date:  2013-03       Impact factor: 2.859

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.